Isabelle Dresco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Isabelle Dresco has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Aude Lachacinski
Patient Safety & Pharmacovigilance, Sanofi Paris France
1 shared publication - Karine Marinier
Real World Solutions , IQVIA , Courbevoie 92400 , France
1 shared publication M. J. Bouvier D'Yvoire
Hoechst Marion Roussel Medical Development, Paris, France
1 shared publication- Marie-Laure Kürzinger
Epidemiology and Benefit Risk, Global R&D, Sanofi Paris France
1 shared publication - Massoud Toussi
Real World Solutions, IQVIA Courbevoie France
1 shared publication - Paul M. Tulkens
Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain (UCLouvain), Brussels, Belgium
1 shared publication
Latest Publications
- Open Access
- 12 November 2024
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 33 (11) , e70046
Effectiveness of the Additional Risk Minimisation Measures for Valproate Among Healthcare Professionals and Patients: A Cross‐Sectional Survey in Six European Countries
Purpose: To assess the impact of the 2018 European additional risk minimisation measures (aRMMs) regarding the use of valproate in women of childbearing potential (WCBP) and during pregnancy.Methods: A cross‐sectional, non‐interventional survey conducted in six European countries among 1982 healthcare professionals (HCPs) (July–October 2020) and 779 WCBP treated with valproate for epilepsy, bipolar disorder or other indications (August 2020–February 2021). HCPs were prescribing physicians (neurologists, psychiatrists, paediatricians and GPs), gynaecologists and pharmacists. Prespecified criteria were defined for success in the dimensions of awareness, knowledge and behaviour (correct answers to ≥ 80% of questions at individual level) and overall success (≥ 90%/80% successful HCPs/patients respectively, in the behaviour dimension and one of the two other dimensions).Results: HCPs and patients did not meet the success criteria either overall or in any dimension. Highest success rates were in the behaviour dimension for gynaecologists (71.7%), pharmacists (49.7%) and patients (51.2%), and in the awareness dimension for prescribing physicians (23.6%). HCPs reported being unfamiliar with some educational materials and lacked knowledge of detailed prescribing conditions for valproate and the need for contraception regardless of sexual activity. More than 50% of patients were aware of the relevant patient materials and knew about the teratogenic risks of valproate.Conclusion: Self‐reported levels of awareness, knowledge and behaviour varied considerably by HCP type and among patient respondents. Further investigation is needed into why certain measures of the pregnancy prevention programme are not well known and followed, to improve their effectiveness. This will be addressed in a qualitative study which will be based on interviews with HCPs and patients.
- 12 November 2024
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 33 (11) , e70046
Open AccessEffectiveness of the Additional Risk Minimisation Measures for Valproate Among Healthcare Professionals and Patients: A Cross‐Sectional Survey in Six European Countries
Purpose: To assess the impact of the 2018 European additional risk minimisation measures (aRMMs) regarding the use of valproate in women of childbearing potential (WCBP) and during pregnancy.Methods: A cross‐sectional, non‐interventional survey conducted in six European countries among 1982 healthcare professionals (HCPs) (July–October 2020) and 779 WCBP treated with valproate for epilepsy, bipolar disorder or other indications (August 2020–February 2021). HCPs were prescribing physicians (neurologists, psychiatrists, paediatricians and GPs), gynaecologists and pharmacists. Prespecified criteria were defined for success in the dimensions of awareness, knowledge and behaviour (correct answers to ≥ 80% of questions at individual level) and overall success (≥ 90%/80% successful HCPs/patients respectively, in the behaviour dimension and one of the two other dimensions).Results: HCPs and patients did not meet the success criteria either overall or in any dimension. Highest success rates were in the behaviour dimension for gynaecologists (71.7%), pharmacists (49.7%) and patients (51.2%), and in the awareness dimension for prescribing physicians (23.6%). HCPs reported being unfamiliar with some educational materials and lacked knowledge of detailed prescribing conditions for valproate and the need for contraception regardless of sexual activity. More than 50% of patients were aware of the relevant patient materials and knew about the teratogenic risks of valproate.Conclusion: Self‐reported levels of awareness, knowledge and behaviour varied considerably by HCP type and among patient respondents. Further investigation is needed into why certain measures of the pregnancy prevention programme are not well known and followed, to improve their effectiveness. This will be addressed in a qualitative study which will be based on interviews with HCPs and patients.
- Open Access
- 1 March 1998
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 41 (suppl 2) , 63-68
Computer-aided prediction of macrolide antibiotic concentrations in human circulating polymorphonuclear leucocytes
The relative in-vivo intracellular concentration of various macrolides in phagocytes cannot be directly extrapolated from in-vitro experiments that use a fixed and constant extracellular concentration for all compounds, since this fails to consider different rates of intracellular penetration, dosage regimens and pharmacokinetic data. In the proposed model, which takes into account the free plasma concentrations and accumulation characteristics of three antibiotics, roxithromycin, azithromycin and erythromycin, we show that roxithromycin and azithromycin may reach similar concentrations in human polymorphonuclear leucocytes when conditions mimic clinical administration of these drugs, while erythromycin concentrations are lower. This approach may be useful to predict the behaviour of other drugs or other cells, and to assist in the design of rational treatment schemes.
- 1 March 1998
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 41 (suppl 2) , 63-68
Open AccessComputer-aided prediction of macrolide antibiotic concentrations in human circulating polymorphonuclear leucocytes
The relative in-vivo intracellular concentration of various macrolides in phagocytes cannot be directly extrapolated from in-vitro experiments that use a fixed and constant extracellular concentration for all compounds, since this fails to consider different rates of intracellular penetration, dosage regimens and pharmacokinetic data. In the proposed model, which takes into account the free plasma concentrations and accumulation characteristics of three antibiotics, roxithromycin, azithromycin and erythromycin, we show that roxithromycin and azithromycin may reach similar concentrations in human polymorphonuclear leucocytes when conditions mimic clinical administration of these drugs, while erythromycin concentrations are lower. This approach may be useful to predict the behaviour of other drugs or other cells, and to assist in the design of rational treatment schemes.